[go: up one dir, main page]

AU2001234493A1 - Compounds and methods for prevention and treatment of her-2/neu associated malignancies - Google Patents

Compounds and methods for prevention and treatment of her-2/neu associated malignancies

Info

Publication number
AU2001234493A1
AU2001234493A1 AU2001234493A AU3449301A AU2001234493A1 AU 2001234493 A1 AU2001234493 A1 AU 2001234493A1 AU 2001234493 A AU2001234493 A AU 2001234493A AU 3449301 A AU3449301 A AU 3449301A AU 2001234493 A1 AU2001234493 A1 AU 2001234493A1
Authority
AU
Australia
Prior art keywords
prevention
compounds
treatment
methods
associated malignancies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001234493A
Inventor
Martin A Cheever
Susan Hand-Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AU2001234493A1 publication Critical patent/AU2001234493A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001234493A 2000-01-21 2001-01-19 Compounds and methods for prevention and treatment of her-2/neu associated malignancies Abandoned AU2001234493A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17754500P 2000-01-21 2000-01-21
US60177545 2000-01-21
PCT/US2001/001850 WO2001053463A2 (en) 2000-01-21 2001-01-19 COMPOUNDS AND METHODS FOR PREVENTION AND TREATMENT OF HER-2/neu ASSOCIATED MALIGNANCIES

Publications (1)

Publication Number Publication Date
AU2001234493A1 true AU2001234493A1 (en) 2001-07-31

Family

ID=22649012

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001234493A Abandoned AU2001234493A1 (en) 2000-01-21 2001-01-19 Compounds and methods for prevention and treatment of her-2/neu associated malignancies

Country Status (5)

Country Link
US (1) US20020039573A1 (en)
EP (1) EP1252294A2 (en)
AU (1) AU2001234493A1 (en)
CA (1) CA2398102A1 (en)
WO (1) WO2001053463A2 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001048205A2 (en) * 1999-12-29 2001-07-05 Corixa Corporation Murine neu sequences and methods of use therefor
DE10042598A1 (en) * 2000-08-30 2002-03-28 Gsf Forschungszentrum Umwelt Recombinant MVA with the ability to express the HER-2 / Neu gene
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
WO2004041065A2 (en) * 2002-10-30 2004-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR PROPHYLAXIS AND TREATMENT OF HER-2/neu TUMORS
PT2489364E (en) 2003-11-06 2015-04-16 Seattle Genetics Inc Monomethylvaline compounds conjugated to antibodies
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
CA2809819A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
MA34277B1 (en) 2010-04-15 2013-06-01 Spirogen Developments Sarl PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
US9000130B2 (en) 2010-06-08 2015-04-07 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN103313990B (en) 2010-11-17 2016-07-20 基因泰克公司 Alanyl maytansinol antibody coupling matter
ES2567276T3 (en) 2011-05-12 2016-04-21 Genentech, Inc. LC-MS / MS method of monitoring multiple reactions to detect therapeutic antibodies in animal samples using frame-changing peptides
DK2750713T3 (en) 2011-10-14 2015-12-21 Medimmune Ltd PYRROLOBENZODIAZEPINS AND CONJUGATES THEREOF
US20150071987A1 (en) * 2012-02-03 2015-03-12 Emory University Immunostimulatory compositions, particles, and uses related thereto
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
KR101995621B1 (en) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
JP6270859B2 (en) 2012-10-12 2018-01-31 エイディーシー・セラピューティクス・エス・アー・エール・エルＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａｒｌ Pyrrolobenzodiazepine-antibody conjugate
JP5993093B2 (en) 2012-10-12 2016-09-14 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepines and their complexes
EP2906296B1 (en) 2012-10-12 2018-03-21 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
HK1216176A1 (en) 2012-12-21 2016-10-21 Medlmmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
WO2014159981A2 (en) 2013-03-13 2014-10-02 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2014229529B2 (en) 2013-03-13 2018-02-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10442836B2 (en) 2013-08-12 2019-10-15 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015095223A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
BR112016013861A2 (en) 2013-12-16 2017-10-10 Genentech Inc drug and antibody conjugates, compounds, treatment method and pharmaceutical composition
BR112016013258A2 (en) 2013-12-16 2018-01-16 Genentech Inc antibody-drug conjugate, pharmaceutical composition, method for treating cancer and kit
CN106687141A (en) 2014-09-10 2017-05-17 麦迪穆有限责任公司 Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2017003123A (en) 2014-09-12 2017-05-12 Genentech Inc Cysteine engineered antibodies and conjugates.
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
SG11201702079UA (en) 2014-09-17 2017-04-27 Genentech Inc Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
BR112017011111A2 (en) 2014-11-25 2017-12-26 Adc Therapeutics Sa pyrrolobenzodiazepine-antibody conjugates
EP3226909A1 (en) 2014-12-03 2017-10-11 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017165542A1 (en) * 2016-03-22 2017-09-28 University Of Florida Research Foundation, Inc. Methods, kit, and compositions for enhancing cellular therapy
CN121431692A (en) 2016-03-25 2026-01-30 豪夫迈·罗氏有限公司 Multiplex total antibodies and antibody conjugated drug quantification assays
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP2019522633A (en) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド PROTAC antibody conjugates and methods of use
JP7022080B2 (en) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド Biochemical analytical methods for the characterization of site-specific antibody-drug conjugates
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
JP7093767B2 (en) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド Pyrrolobenzodiazepine prodrug and its antibody conjugate
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
HUE054689T2 (en) 2017-02-08 2021-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
SI3612537T1 (en) 2017-04-18 2022-10-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
EP3612234B1 (en) 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
CA3064804A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
SG11202000358YA (en) 2017-08-18 2020-02-27 Medimmune Ltd Pyrrolobenzodiazepine conjugates
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
JP2022513198A (en) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Photocrosslinkable peptide for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
MX2021010477A (en) 2019-03-15 2021-10-01 Medimmune Ltd Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer.
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
AU2021362997A1 (en) 2021-11-03 2024-05-16 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
CN121263210A (en) 2023-04-17 2026-01-02 沛科生物公司 Antibodies and antibody-drug conjugates, as well as their usage, synthesis processes, and intermediates
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
JP2002515734A (en) * 1996-01-02 2002-05-28 カイロン コーポレイション Immunostimulation mediated by genetically modified dendritic cells

Also Published As

Publication number Publication date
WO2001053463A2 (en) 2001-07-26
EP1252294A2 (en) 2002-10-30
CA2398102A1 (en) 2001-07-26
WO2001053463A3 (en) 2002-02-14
US20020039573A1 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
AU2001234493A1 (en) Compounds and methods for prevention and treatment of her-2/neu associated malignancies
HUP0600780A2 (en) Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
AU2212299A (en) Compositions and methods for the treatment of tumor
AU6147401A (en) Compositions and methods for the treatment of cancer
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
EP1176964B8 (en) Uses of et743 for treating cancer
AU3784999A (en) Methods for treatment of pain
AU2001286983A1 (en) Method of treatment
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
AU2001240046A1 (en) Method of treating skin conditions
AU2001259817A1 (en) Methods of and compounds for inhibiting calpains
AU2001232263A1 (en) Method of treating seeds
AU2001253836A1 (en) Method of treating cancer
AUPR644301A0 (en) Method and composition for treatment of cancer
AU6970101A (en) Method for treatment and prevention of mastitis
AU2566201A (en) Compounds and methods for the treatment of pain
AU2420101A (en) Method and composition for the treatment of pain
AU2001262177A1 (en) Method of treatment
AU2003286770A1 (en) METHODS FOR PROPHYLAXIS AND TREATMENT OF HER-2/neu TUMORS
AU2292801A (en) Compositions and methods for treatment of breast cancer
AU2420201A (en) Compounds and methods for the treatment of pain
AU2390700A (en) Polypeptidic compositions and methods for the treatment of tumors